A bold title, perhaps, but GLP-1 agonists have certainly earned their moment in the spotlight.
Whenever a new medicine arrives, we are quick to call it a “breakthrough.” But only a handful of medicines truly change not just how we treat a disease, but how we think about the disease itself.
GLP-1 agonists may be one of them.
What are GLP-1 agonists?
Originally developed to help people with type 2 diabetes, GLP-1 receptor agonists mimic the action of a hormone naturally released by our gut after we eat. They help control blood sugar, slow stomach emptying, and send signals to the brain that say, “Thanks, we’ve had enough.”
More than just blood sugar
Then came another remarkable effect: weight loss.
Today, GLP-1 based medicines are changing how doctors approach diabetes and obesity, with some also demonstrating important cardiovascular and other health benefits in certain groups of patients.
These benefits depend on the particular medicine and the individual patient. The choice of treatment should take into account medical history, other medicines and overall health goals.
A shift in how we think about obesity
But perhaps their biggest contribution is not measured in kilograms or blood sugar numbers. They are helping change the conversation around obesity from simply telling people to “eat less and move more” to recognizing obesity as a complex, chronic disease influenced by biology, hormones, genetics and environment.
Medicines are one part of that approach. Healthy eating, physical activity and ongoing support remain important, with care tailored to each person’s needs.
Not without limitations
Of course, even a GOAT has limitations. GLP-1 medicines can cause nausea, vomiting, constipation and other side effects, and they are not appropriate for everyone. Like any powerful medicine, they need to be prescribed thoughtfully and used under medical supervision.
Regular follow-up helps assess how well treatment is working and whether it is being tolerated. Anyone considering GLP-1 treatment should discuss its potential benefits and risks with their endocrinologist before starting.
So, are GLP-1 agonists really the GOAT of modern medicine?
Perhaps it’s too early to hand them the trophy.
But they have already achieved something few medicines do: they haven’t just changed the treatment, they’re changing the way we think about the disease.
This article provides general health information and does not replace an individual medical assessment.